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Abstract
The spinal cord is unable to regenerate after injury largely due to growth-inhibition by an inflamma-
tory response to the injury that fails to resolve, resulting in secondary damage and cell death. An
approach that prevents inhibition by attenuating the inflammatory response and promoting its reso-
lution through the transition of macrophages to anti-inflammatory phenotypes is essential for the
creation of a growth permissive microenvironment. Viral gene delivery to induce the expression of
anti-inflammatory factors provides the potential to provide localized delivery to alter the host inflam-
matory response. Initially, we investigated the effect of the biomaterial and viral components of the
delivery system to influence the extent of cell infiltration and the phenotype of these cells. Bridge
implantation reduces antigen-presenting cell infiltration at day 7, and lentivirus addition to the bridge
induces a transient increase in neutrophils in the spinal cord at day 7 and macrophages at day 14.
Delivery of a lentivirus encoding IL-10, an anti-inflammatory factor that inhibits immune cell activa-
tion and polarizes the macrophage population towards anti-inflammatory phenotypes, reduced
neutrophil infiltration at both day 7 and day 28. Though IL-10 lentivirus did not affect macrophages
number, it skewed the macrophage population toward an anti-inflammatory M2 phenotype and
altered macrophage morphology. Additionally, IL-10 delivery resulted in improved motor function,
suggesting reduced secondary damage and increased sparing. Taken together, these results indicate
that localized expression of anti-inflammatory factors, such as IL-10, can modulate the inflammatory
response following spinal cord injury, and may be a key component of a combinatorial approach that
targets the multiple barriers to regeneration and functional recovery.
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1 | INTRODUCTION
To date, the only treatment for treating spinal cord injury (SCI) with
any degree of success in clinical trials is methylprednisolone, which mit-
igates the inflammatory response after injury.1 Inflammation after SCI
initiates a damaging secondary injury response that establishes multiple
barriers (e.g., accumulation of myelin debris, and reactive gliosis) to
regeneration and restoration of function. The inflammatory cascade
begins with upregulated production of inflammatory cytokines, chemo-
kines, and reactive oxygen species (ROS),2–5 which leads to recruitment
of peripheral immune cells6 and activation of local microglia, oligoden-
drocytes, and astrocytes.7–10 Early recruitment of neutrophils (PMNs)—
and later macrophages—comprises the innate immune response to SCI.
PMNs and macrophages recruited to the injury can remove pathogens;
however, they also propagate secondary injury, which results in death
of neurons and oligodendrocytes.11,12 Macrophages, in particular, also
phagocytose debris left behind by necrotic or apoptotic cells, including
inhibitory myelin debris whose slow clearance contributes to the inabil-
ity of axons to regenerate.13,14 In addition, inflammatory cytokines pro-
duced by PMNs and macrophages induce astrocytes to adopt a
reactive state in which they proliferate and can increase the secretion
of chondroitin sulfate proteoglycans (CSPGs). These reactive astrocytes
then form an inhibitory glial scar that surrounds the injury site and pre-
vents regenerating axons from crossing.9,14–19
In normal wound healing, the inflammatory response resolves over
time, leaving behind regenerated, functional tissue. In contrast, SCI results
in a chronic immune response characterized by the persistence of inflam-
matory cells, insufficient clearance of cellular debris at the injury, and for-
mation of a robust glial scar that creates a barrier that limits
regeneration.12,20,21 In peripheral tissues, a transition in macrophage phe-
notype from inflammatory (M1 or classically activated) to anti-
inflammatory (M2 or alternatively activated) is largely responsible for
dampening and resolving the immune response after injury.22–24 How-
ever, this transition does not occur on a sufficient scale after SCI. Instead,
M1 macrophages chronically persist in zones of axon degeneration, where
they propagate inflammation and inhibit axon regeneration.25–30 Though
a preponderance of evidence has shown that M1 macrophages predomi-
nate within the injury site after SCI, M2 macrophages are present—typi-
cally peaking at day 14 after injury in rodents.31 M2 macrophages
generally have enhanced phagocytic capabilities32,33 and can promote
axon growth across inhibitory boundaries in vitro.25 They stimulate tissue
repair through attenuated production of inflammatory cytokines, reduced
ROS production, and expression of pro-resolving cytokines such as IL-
10.34 In contrast, M1macrophages are characterized by increased produc-
tion of pro-inflammatory cytokines, ROS and NO—each of which leads to
neuron and oligodendrocyte toxicity.25,35 Several factors promote M2
phenotypes including IL-4, IL-13, glucocorticoids, and IL-10. Of these, IL-
10 was selected for this study due to its ability to promote neuron survival
while reducing leukocyte infiltration and activation.36–38
Macrophage depletion has been investigated as a potential solution
to mitigate the inflammatory response, but there have been mixed results.
Treatment with liposome-encapsulated clodronate to deplete hematoge-
nous macrophages improved partial hindlimb recovery and tissue repair in
one study39 and decreased fibrotic scarring while increasing axon num-
bers in a second study.40 In contrast, antibody-mediated depletion of
CD11c1 monocytes/macrophages or conditional ablation by diphtheria
toxin each reduced functional recovery.41 These seemingly contradictory
results suggest that specific macrophages phenotypes may have different
effects on tissue repair and that eliminating or enhancing specific subtypes
may be more beneficial than targeting the entire macrophage population.
Additionally, there may be unintended systemic or local consequences of
depleting the entire population, such as increased susceptibility to infec-
tion and disease and reduced clearance of inhibitory debris.
While macrophage phenotype has often been depicted as a binary
system where a cell is either M1 or M2 at any given time, it is now
thought that macrophages exist along a continuous spectrum of activa-
tion states, with M1 and M2 as polar opposites.23,42 For example,
some reports have sub-divided M2 macrophages into additional sub-
types (e.g., M2a, M2b, and M2c), each of which has a role in suppress-
ing inflammation. The M2a (alternative) macrophages are involved in
initial wound healing and the Th2-type (T-cell mediated) inflammatory
response, while M2b (type 2) macrophages are believed to be immu-
noregulatory. Finally, M2c (deactivated) macrophages are immunosup-
pressive and facilitate matrix deposition and issue remodeling.43,44
Despite observations of these macrophage subtypes in vitro, it remains
unclear how this correlates with macrophage activation in vivo. Macro-
phages retain inherent capacity for plasticity along this activation spec-
trum, dynamically responding to changes in their local environment.36,45
This dynamic plasticity makes macrophages a compelling target for
resolving inflammation in the spinal cord to enable regeneration.
In addition to addressing neuroinflammation, therapies for spinal
cord regeneration must provide physical support and guidance for
regenerating axons across the injury site. SCI therapies focused solely
on resolution of neuroinflammation have largely failed due to both lack
of a growth-promoting substrate and accumulation of inhibitory factors
at the injury.46,47 While immunomodulatory strategies can reduce
inflammation and promote axonal sparing, guidance of regenerating
axons requires a permissive substrate. Initial attempts to provide a per-
missive bridge across spinal cord lesions implanted donor peripheral
nerve grafts.48 More recently, synthetic multiple-channel bridges have
been developed to replicate the synergistic advantages of peripheral
nerve grafts—physical support and guidance and a biologically active,
pro-regenerative microenvironment.49–54 We have previously demon-
strated that multiple-channel bridges made from biodegradable poly
(lactide-co-glycolide (PLG) support robust crossing of axons across the
lesion site, resulting in formation of regenerated axon bundles after
complete bridge degradation 6 months after SCI.54,55 Longitudinal,
macroscale channels within these bridges act as conduits for axons
regenerating across the injury site, while scaffold microporosity sup-
ports host cell infiltration and tissue integration.55,56
Herein, we investigate the hypothesis that localized lentiviral
expression of IL-10 from multiple-channel PLG bridges will modulate
the numbers, phenotypes, and proportions of leukocyte populations
infiltrating the bridge to promote a “resolving” anti-inflammatory envi-
ronment thought to be more permissive to regeneration. In addition to
providing a substrate for regeneration, PLG bridges have also served as
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a platform for localized delivery of gene therapy vectors that can induce
the expression of therapeutic proteins.54,57 Biomaterial-mediated lenti-
virus delivery after SCI efficiently transduces infiltrating cells to yield a
localized, stable pattern of gene expression.54,58 Lentiviral particles asso-
ciated with the heparin-modified PLG bridges, which functions to retain
the vector locally and can increase its half-life for enhanced gene trans-
fer. Infiltrating host cells are transduced by the lentivirus, with peak
transgene expression occurring approximately 7 days after bridge trans-
plantation with sustained expression for at least 8 weeks.54,58 Expres-
sion of IL-10 will be investigated due to its neuroprotective and anti-
apoptotic properties, as well as its ability to skew macrophages towards
anti-inflammatory phenotypes.36,59 The studies focus on the first four
weeks after injury comprising the acute, subacute, and intermediate
phases of recovery, which encompasses the time over which many of
the barriers to regeneration become established.
2 | MATERIALS AND METHODS
2.1 | Virus production
Lentivirus was produced by co-transfecting HEK-293T cells with third
generation lentiviral packaging vectors (pMDL-GagPol, pRSV-Rev,
pIVS-VSV-G,60 and the gene of interest (pLenti-CMV-Luciferase or
pLenti-CMV-IL-10) using Lipofectamine 2000 (Life Technologies,
Grand Island, NY, USA). After, lentiviral particles were purified using
the Lenti-X Maxi Purification Kit (Clontech Laboratories, Mountain
View, CA, USA) and then concentrated using Vivaspin centrifugal con-
centrators (Sartorius, G€ottingen, Germany). Viral titers used throughout
the study were 2E10 IU/ml as determined by the Lentivirus qPCR Titer
Kit (Applied Biological Materials, Richmond, BC, Canada).
2.2 | Fabrication of multiple-channel bridges
Bridges were fabricated using a sacrificial template variation61 of the gas
foaming/particulate leaching technique,54 as previously described.62
Briefly, PLG (75:25 lactide:glycolide; inherent viscosity 0.76 dl/g; Lake-
shore Biomaterials, Birmingham, AL, USA) was dissolved in dichlorome-
thane (6% w/w) and emulsified in 1% poly(vinyl alcohol) using a
homogenizer (PolyTron 3100; Kinematica AG, Littau, Switzerland) at
3000 rpm to create microspheres (z-average diameter 1mm). D-sucrose
was caramelized, cooled, and drawn from solution with a Pasteur pipette
to make sugar fibers. These fibers were coated with a mixture of PLG
microspheres and salt (63–106 lm) and pressed into a salt-lined aluminum
mold. The materials were then equilibrated with CO2 gas (800 psi) for 16
hrs and then gas foamed in a custom-made pressure vessel. Bridges were
subsequently cut into 2.25 mm sections and leached for 2 hrs to remove
porogens. The bridges are dried overnight and stored in a desiccator.
2.3 | Heparinization of nerve bridges
Heparin coating of bridges has been shown to enhance lentiviral load-
ing and transduction from bridges in vivo.63 PLG bridges were incu-
bated with chitosan (Sigma Aldrich, St. Louis, MO, USA; 25 lg/ll in 2%
glacial acetic acid) for 10 min, followed in a N-(3-dimethylamino-
propyl)-N0-ethylcarbodiimide/N-hydroxylsuccinimide (Sigma Aldrich)
mixture dissolved in 2-(N-morpholino)ethanesulfonic acid (EDC/NHS in
MES; 1.5:1:1 mg/mg/ml, Sigma Aldrich) for 2 hrs. To conjugate chito-
san, bridges were washed 3 times with water, dried and subsequently
incubated with heparin (Sigma Aldrich; 25 lg/ll in 1MMES) for 10 min
followed by EDC/NHS in MES for an additional 2 hrs for covalent con-
jugation. Finally, bridges were washed in water three times and dried.
2.4 | Virus loading onto heparinized nerve bridges
Multiple additions of viruses were adsorbed onto bridges in an iterative
manner in order to increase lentiviral loading. Prior to virus addition, bridges
were disinfected in 70% ethanol and washed with water. After 12 min of
drying time, bridges were saturated with 2 ll of virus. Bridges were then
dried for an additional 12 min followed by another 2 ll of virus. Bridges
were then dried for 14 additional min followed by a final 2 ll of virus. After
a final 5 min of drying, bridges were stored at2808C until used for surgery.
2.5 | Mouse spinal cord hemisection
A hemisection model of SCI was performed as previously described62
on female C57/BL6 mice (4-6 weeks-old; Charles River Laboratories,
Wilmington, MA, USA), according to the Animal Care and Use Commit-
tee guidelines at Northwestern University. A laminectomy was per-
formed at T9-T10 to allow for a 2.25 mm lateral hemisection for bridge
implantation. The injury site was covered using Gelfoam (Pfizer, New
York, NY, USA) followed by suturing together of the muscle and sta-
pling of skin. Postoperative care consisted of administration of enroflox-
acin (2.5 mg/kg; daily for 2 weeks), buprenorphine (0.1 mg/kg; twice
daily for 3 days), and Lactated Ringer’s solution (5 ml/100 g; daily for 5
days). Bladders were expressed twice daily until function recovered.
2.6 | Tissue processing and immunofluorescence
Spinal cord tissue was collected at days 7, 14, and 28, which were cho-
sen to represent acute, subacute and intermediate phases of regenera-
tion respectively. It may be noted that days 7 and 14 are at the tail end
of their respective phases; however, it is not possible to extract the spi-
nal cord and bridge together prior to day 7 as the bridge falls out due
to a weak interface tissue-bridge interface. Additionally, cellular infiltra-
tion is lower at earlier time points, making flow cytometry challenging.
For immunofluorescence, spinal cord segments were then snap frozen
in isopentane and embedded in Tissue Tek O.C.T. Compound (Sakura
Finetek, Torrance, CA, USA) with 20% sucrose. Cords were cryo-
sectioned transversely in 18-lm-thick sections.
Antibodies against the following antigens were used for immunofluo-
rescence: neurofilament 200 (NF200, Sigma Aldrich), myelin basic protein
(MBP, Santa Cruz Biotech, Dallas, TX, USA) P-zero myelin protein (P0)
(Aves Labs, Tigard, OR) F4/80 (AbD Serotec, Raleigh, NC, USA) arginase I
(clone N20, Santa Cruz Biotech) and Ly-6G (clone RB6-8C5, Biolegend).
Using stained tissue sections, immuno-positive cells and axons within
the bridge area were quantified manually by two blinded researchers
independently. Co-staining for multiple markers was assessed by evaluat-
ing pixel overlap of different channels in NIH ImageJ (Bethesda, MD,
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USA). Total numbers of F4/801 cells and numbers of F4/801/arginase1
cells were evaluated to determine numbers of total macrophages and
M2 macrophages, respectively. Macrophages were identified by localizing
Hoechst nuclear staining to F4/801 immunofluorescence and labeling
them in ImageJ. Subsequently, each identified F4/801 cell was binned
based on having arginase immunofluorescence visible over background.
Cell counts were then normalized to counted area in each tissue section.
Macrophage shape was characterized for each positive cell and cells
were binned as fibrous/elongated, round and not ruffled with a bright
F4/801 perimeter, or as multinucleated foreign body giant cell (FBGC).
To assess the numbers of regenerated and myelinated axons, NF200
was used to identify axons, NF2001/MBP1 to determine the number of
myelinated axons, and NF2001/MBP1/P01 to determine the amount of
myelin derived from infiltrating Schwann cells.57
2.7 | Flow cytometry of digested tissue samples
Flow cytometry was performed on spinal cord bridge implants loaded
with no lentivirus, lentivirus encoding firefly luciferase (FLUC) or IL-10
to determine the identity of infiltrating cells 7, 14, and 28 days after
injuries. Spinal cord hemisection with no bridge implants were also per-
formed. To isolate sufficient cell numbers for flow cytometry, implant
sites from 3 individual mice were pooled together per condition. Bridge
tissue samples were mechanically dissociated by 16g needle and
syringe and digested in a solution containing collagenase (1 mg/ml;
Worthington Biochemical Corp., Lakewood, NJ, USA) and trypsin
(0.5 mg/ml; Life Technologies) for 20 min at 378C. After incubation,
1 ml of fetal bovine serum (Sigma Aldrich) was immediately added to
inhibit digestion and solution was triturated with fire-polished glass
pipettes of at least three successively decreasing diameters to achieve
a single cell suspension. Digested tissues were pushed through 70 lm
strainers and washed with Hank’s Balanced Salt Solution without cal-
cium and magnesium (VWR, Radnor, PA, USA). Cells were then sepa-
rated from myelin using the OptiPrep gradient system (Sigma Aldrich)
in MOPS buffer, as previously described by Beck et al.20 Cells were
subsequently blocked with a solution containing 1% normal mouse and
rat serum (Sigma Aldrich) and anti-mouse CD16/32 (eBioscience) and
stained for viability using fixable violet dead cell stain (Invitrogen) and
stained with the specific antibodies listed above. Data were acquired
on a BD LSR II cytometer, and analyzed using FloJo software. Fluores-
cence minus one staining was used as a negative control.
The following flow cytometry antibodies were used: v500-
conjugated 30-F11 against CD45, PE(phycoerythrin)/Cy7-conjugated
RM4-5 against CD4, and Alexa Fluor 647-conjugated 1B4 against
GFAP (glial fibrillary acidic protein) (BD Biosciences, San Jose, CA, USA),
PE-conjugated N418 against CD11c, APC/eFluor780-conjugated BM8
against F4/80 (eBioscience, San Diego, CA, USA), PerCP-conjugated
RB6-8C5 against Gr-1 (high affinity Ly-6G, low affinity Ly-6C,64,65 Biol-
egend, San Diego, CA, USA). Unconjugated antibody against CNPase
(20 ,30-cyclic-nucleotide 30-phosphodiesterase) was purchased from
Abcam and conjugated to fluorescein isocyanothionate (FITC) using an
EasyLink Conjugation kit (Abcam, Cambridge, MA, USA).
2.8 | mRNA isolation and qRT-PCR analysis
To isolate mRNA, spinal cord tissues and bridge implants were
explanted with 2 mm of spinal cord both rostral and caudal to the
bridge. Explanted tissues were homogenized using 1 ml of Trizol rea-
gent (Life Technologies) with a tissue grinder. RNA isolation was fol-
lowed by chloroform extraction and isopropanol precipitation.66 The
extracted RNA was dissolved in 30 ll of RNase-free distilled water
and RNA concentration was measured using a NanoDrop 2000C (Ther-
moFisher Scientific, Newark, DE, USA) and to assure sufficient purity
(A260/A280 ratios between 1.9 and 2.1 for all samples). Total isolated
RNA was stored at 280C freezer until use. cDNA was synthesized
using iScriptTM cDNA Synthesis kit (Bio-Rad, Hercules, CA, USA)
according to the manufacturer’s instructions using 1 mg of RNA per
sample.
Primers for qRT-PCR (quantitative real-time polymerase chain
reaction) quantification of arginase I expression were chosen based on
a previous study25: forward 50-GAACACGGCAGTGGCTTTAAC-30, and
reverse 50- TGCTTAGCTCTGTCTGCTTTGC-30. 18s-rRNA was used as
an internal control with following sequences: forward 50-
GCAATTATTCCCCATGAACG-30 , and reverse 50- GGCCTCACTAAAC-
CATCCAA-30.67 The qRT-PCR products were measured using the accu-
mulation level of iQTM SYBR Green Supermix (Bio-Rad) fluorescence
following a manufacturer’s protocol on CFX ConnectTM Real-Time PCR
Detection System (Bio-Rad). The gene expression level of arginase I
mRNA was normalized to that of 18s-rRNA and differences in gene
expression were presented as fold ratios from sham (laminectomy
only) spinal cord samples. Relative quantification was calculated as
X522DDCt, where DDCt5DE2DCt and DE5Ct,exp – Ct,18s-rRNA,
DCt5Ct, sham – Ct,18s-rRNA.
68
2.9 | Behavioral analysis
The Basso mouse scale (BMS) open-field locomotor test (range 0–9)
was used to assess functional recovery for a period 24 weeks after
SCI as previously described.69 A baseline was determined prior to
SCI, and mice were tested 3, 7, 14, 21, and 28 days. Observations
and BMS scoring were performed by two trained observers at 4-min
intervals.
2.10 | Statistical analysis
For multiple comparisons, statistical significance between groups was
determined by one-way or two-way ANOVA with Tukey’s post hoc
testing or Sidak post hoc testing. For single comparisons, the statistical
significance between pairs was determined by unpaired t test. For, sta-
tistical analysis of macrophage histology, data sets were standardized
using an ln(x11) transformation to eliminate skewness and normalize
to a Gaussian distribution as verified with D’Agostino-Pearson omnibus
test.70 All statistics test significance using a p value of .05 unless other-
wise noted. Error bars represent standard error in all figures. Prism 7
(GraphPad Software, La Jolla, CA, USA) software was used for all data
analysis.
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3 | RESULTS
3.1 | Cell infiltration into bridges
Cell infiltration into the bridges was initially investigated to identify the
cell populations and their abundance at multiple time points. No statis-
tically significant changes in the numbers of CD451 immune cells or
GFAP1 reactive astrocytes were observed within the bridges between
days 7 to 28 (Figure 1A). Additionally, although no significant decrease
in CNPase1 oligodendrocytes was observed during this time, a trend
towards decreasing abundance was seen (Figure 1A). When sub-
populations of CD451 immune cells were assessed, a significant
increase in the percentage of F4/801 macrophages was observed from
day 7 to day 14 (Figure 1B). Numbers of Gr-11 neutrophils (PMNs)
and CD11c1 dendritic cells (DCs) did not significantly change over
time. Finally, CD41 helper T (TH) cells had a significant increase in
abundance from days 14 to 28, indicating that the adaptive immune
response is activated at later time points.
3.2 | IL-10 gene delivery from bridges reduces PMN
infiltration
The immune response to bridges with and without delivery of IL-10-
encoding lentivirus was investigated to determine if the infiltration of
inflammatory cells can be modulated through localized cytokine expres-
sion. In previous reports, we have demonstrated lentiviral IL-10 expres-
sion36 and sustained transgene expression for at least 8 weeks in the
injured spinal cord.63 The flow cytometry studies were performed at
days 7 and 28, to capture differences from the acute to intermediate
phases of recovery observed in Figure 1. First, though differences in infil-
trating immune cells (CD451) as a percentage of total cells were not stat-
istically different at day 7, the addition of a bridge to the SCI resulted in
a 38% decrease and the addition of lentivirus to the bridge resulted in a
23–34% increase over the bridge alone (Figure 2). This result indicates
that the bridge may participate in stabilizing the injury and reducing
inflammation at early time points. From day 7 to 28, hemisection alone
(no bridge implantation) and bridges loaded with either lentivirus had a
reduction of greater than 50% (p< .05) in CD451 cells as a percentage
of total cells. Bridges without lentivirus had only a 33% reduction over
this same time. At day 28, immune cells as a percentage of total cells
were similar for all conditions. Subpopulations of CD451 immune cells
were characterized at days 7 and 28 with all bridge conditions having a
2-fold decrease in the percentage of CD11c1 antigen-presenting cells
(APCs, including dendritic cells and macrophages) relative to no bridge
implantation at day 7 (Figure 3A). This reduction did not persist to day
28, at which point APC numbers were similar across all conditions.
FIGURE 1 Time course of immune cell infiltration into spinal cord bridges. Infiltrating cells form the central nervous system and peripheral
immune system were identified in bridges implanted into a hemisection spinal cord injury (n56–21 mice) (A) CD451 immune cell, GFAP1
astrocyte, and CNPase1 oligodendrocyte infiltration into bridges were quantified as a percentage of total cells using flow cytometry at days
7, 14, and 28. (B) Immune sub-populations, including CD11c1 dendritic cells, F4/801 macrophages, Gr-11 neutrophils, and CD41 helper T
cells, in the bridge were quantified as a percentage of total immune cells using flow cytometry at days 7, 14, and 28. Statistical analysis
completed using a one-way ANOVA with Tukey’s post hoc test. Significantly different groups denoted by letter with “a” and “b” denoting
statistical significance between the two groups (p <.05)
FIGURE 2 Bridge implantation and lentivirus delivery do not increase
immune cell infiltration. The infiltration of immune cells into the injury
site after hemisection spinal cord injury were quantified as a
percentage of total cells by flow cytometry at days 7 and 28 (n59–15
mice). A mock implantation consisting of the hemisection injury without
bridge implantation (no bridge) was compared to bridge implantation,
luciferase control lentivirus (vCtrl) loaded bridge implantation, and IL-10
lentivirus (vIL-10) loaded bridge implantation. Statistical analysis was
completed using a two-way ANOVA with a Sidak correction for multi-
ple comparisons. Significant differences between days 7 and 28 notated
with ** (p <.01) or * (p <.05)
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Interestingly, the hemisection-only condition had a dramatic 3.5-fold
(p< .01) decrease in APC infiltration. The percentage of infiltrating F4/
801 macrophages as percent of CD451 cells was reduced approximately
2-fold in the bridge conditions relative to the no bridge control at day 7;
however, by day 28, the macrophage percentage increased in the bridge
conditions such that they were no longer significantly less than the no
bridge condition (Figure 3B). Notably, these changes represent the per-
centage of CD451 cells that were also F4/801; thus, the increase in
macrophage percentage at day 28 does not imply an increase in the total
number of macrophages. Finally, delivery of IL-10-encoding lentivirus
reduced numbers of infiltrating PMNs by 3.5-fold when compared to the
bridges loaded with control lentivirus at Day 7 (p< .05) (Figure 3C).
Bridges loaded with IL-10-encoding lentivirus had similar numbers of
infiltrating PMNs as in hemisections with no bridge implant. Localized IL-
10 expression at the bridge did sustain a 3.5-fold reduction of PMN infil-
tration through day 28 (relative to the no bridge control) (p< .05) (Figure
3C). Additionally, IL-10 expression reduced the mean level of PMN infil-
tration by 2.4-fold compared to all other bridges, though this decrease
was not statistically significant (Figure 3C).
3.3 | IL-10 gene delivery from bridges increases M2
macrophage infiltration
Immunofluorescence staining of tissue sections was applied to investi-
gate morphological features and distribution of immune cells, which
complements the flow cytometry characterization of the relative popu-
lations of immune cells infiltrating the bridge.
Immunofluorescently stained sections were initially analyzed to
quantify densities of total macrophages (F4/801) and M2 macrophages
(F4/801/arginase1) (Figure 4). A statistical difference (p< .05) was
FIGURE 3 IL-10 delivery from bridge reduces neutrophil infiltration. The infiltration of immune cell sub-populations into the injury site
was investigated for no bridge, bridge, luciferase control lentivirus (vCtrl) loaded bridges, and IL-10 lentiviral (vIL-10) loaded bridges (n56–
21 mice). Infiltration of sub-populations of innate immune cells were quantified by flow cytometry at day 7 and day 28 including (A)
CD11c1 dendritic cells, (B) F4/801 macrophages, and (C) Gr-11 neutrophils. Statistical analysis completed using a one-way ANOVA with
Tukey’s post hoc test. Significantly different groups denoted by letter with “a” and “b” denoting statistical significance between the two
groups p< .05 for Gr-1 and p< .005 for all others
FIGURE 4 IL-10 delivery increases the density of M2 macrophages. (A) Immunofluorescence (F4/801/arginase1/Hoechst1: Red/Green/Blue,
respectively) was used to characterize the phenotype of infiltrating macrophages within the bridge (scale bar 200 mm). Line indicates the bridge
area used for quantification and dashed line indicates higher magnification regions in (B) F/4801 total macrophages (C) arginase1 cells, and (D)
merge (scale bar 50 mm). Brightness and contrast were adjusted for clarity. Arrows note arginase- macrophages (white) and arginase1
macrophages (yellow). (E) Quantification of density (cells/mm2) of total F4/801 macrophages as counted manually. (F) Quantification of density
(cells/mm2) of F4/801/arginase1 M2 macrophages as counted manually. For all quantification, mean 1/2 SEM was plotted and n 3 where
each replicate is an average of 1–4 tissues from an individual animal. Statistical analysis was completed on log normalized data using a two-way
ANOVA with Tukey’s post hoc test with statistical significance between groups indicated by a single asterisk (p <.05). Statistical significance of
individual conditions between time points indicated by letter with “a” and “b” denoting statistical significance between the two groups (p< .05)
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observed in macrophage density between days 14 and 28 for delivery
of lentivirus (encoding FLUC or IL-10) from the bridge. In agreement
with the flow cytometry results, macrophage number was similar
between days 7 and 28 for all conditions (Figure 4E). We subsequently
characterized the density of F4/801 cells that also expressed arginase,
a marker for the M2 macrophage phenotype. A significant increase in
arginase1 macrophage density was observed at day 14 in the bridges
loaded with IL-10-encoding lentivirus relative to control bridge
implants (no lentivirus) (Figure 4F), with a similar trend observed rela-
tive to FLUC loaded bridges.
The morphology of the F4/801 cells was subsequently character-
ized to further represent macrophage phenotype. The F4/801 cells
were categorized according three distinct morphologies. The first mor-
phology consisted of fibrous, elongated cells that appeared to have
multiple processes (Figure 5A). A second morphology was round and
had a prominent F4/801 border, and a majority of these round cells
were arginase1 (Figure 5B). The third F4/801 morphology consisted of
multinucleated foreign body giant cells (FBGCs) (Figure 5C), and nearly
every nucleus in the FBGCs was surrounded by arginase1 immuno-
staining. Each macrophage was binned according to arginase expres-
sion and morphology (fibrous, round, or FBGC). For the fibrous
macrophages, the density was largely consistent across conditions and
time points, with the singular exception of a 5.5-fold decrease in den-
sity between days 14 and day 28 for the control virus condition (Figure
5D). For the round macrophages, no significant differences were
observed, though a strong trend (p5 .088) toward an increase in
arginase1 round macrophages was identified for IL-10 expression rela-
tive to FLUC across all time points (Figure 5E). Finally, for the FBGCs, a
greater density of the arginase1 cells was observed at Day 14 for the
IL-10 conditions relative to the FLUC virus control (Figure 5F).
3.4 | IL-10 delivery results in elevated arginase
expression
mRNA levels for arginase were measured by qRT-PCR to complement
the arginase1 cells density assessment by immunofluorescence. At day
7, qRT-PCR revealed a 5-fold or greater increase in arginase mRNA in
the IL-10 group (p< .001) (Figure 6). Increased mRNA at day 7 may
FIGURE 5 IL-10 alters macrophage morphology. Immunofluorescence (F4/801/arginase1/Hoechst1: red/green/blue, respectively), was
used to characterize the morphology of infiltrating macrophages within the bridge as either (A) fibrous, (B) round, or (C) FBGC (scale bar 50
mm). Arrows note arginase- macrophages (white) and arginase1 macrophages (yellow). (D) Manual quantification of density (cells/mm2) of
fibrous macrophages. (E) Manual quantification of density (cells/mm2) of round macrophages. (F) Manual quantification of density (fused
nuclei/mm2) of FBGC macrophages. For all quantification, mean 1/2SEM was plotted and n 3 where each replicate is an average of 1–4
tissues from an individual animal. Statistical analysis was completed on log-normalized data using a two-way ANOVA with Sidak correction
for multiple comparisons with statistical significance indicated by a single asterisk (p< .05)
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correlate to increased protein observed in tissue sections at Day 14
(Figure 4F). At day 14, arginase expression in IL-10 bridges was ele-
vated almost 5-fold compared to bridges loaded with FLUC-encoding
lentivirus (p< .0001). At day 28, arginase mRNA levels remained more
than 2-fold higher for the IL-10 condition, but this difference was not
statistically significant (.08< p< .13)
3.5 | Axon regeneration and myelination
Axon numbers and myelination were quantified at day 28 to assess
whether IL-10 overexpression would prove detrimental, which has
been reported in the peripheral nervous system.71 Myelinated
(NF2001/MBP1) and unmyelinated (NF2001/MBP-) axons were
seen throughout the bridges in animals receiving no lentivirus,
FLUC-encoding control lentivirus, or IL-10-encoding lentivirus (Fig-
ure 7A–D) 28 days after SCI. NF2001 axons were typically observed
as bundles as previously reported for multichannel PLG
bridges.54,57,72 Empty bridges had approximately 800 neurites/mm2,
and both lentiviral conditions had approximately 1100 neurites/
mm2. While the data suggest a trend toward greater densities of
regenerating axons with lentivirus delivery, these differences were
not statistically significant. Similarly, the percentage of axons that
were myelinated (22–34%) or the percentage of myelination that
was derived from Schwann cells (15–35%) did not vary between
conditions (Figure 7E).
3.6 | Motor function is improved with IL-10
Motor function in the ipsilateral hindlimb was characterized over the
first 28 days after SCI using the BMS (Figure 8). Prior to surgery, all
mice had full function, and 3 days post injury, no movement was
observed in the ipsilateral hindlimb of any mice. From day 14
onward, mice receiving IL-10 lentivirus had substantially improved
function in comparison mice that received a bridge without lentivi-
rus. Mice receiving IL-10 lentivirus received a BMS score of 4.4,
where 4 indicates the capacity to take a step (defined as having
weight support at lift off, forward limb advancement, and re-
establishment of weight support at initial contact) and 5 indicates
that stepping occurs at least 50% of the time. In contrast, without
IL-10, mice scored an average of 3, which only indicates plantar
placement of the foot while moving.
FIGURE 6 Il-10 results in elevated arginase mRNA. qRT-PCR
revealed elevated arginase levels at 7 and 14 days after SCI. Levels
statistically returned to baseline by day 28, but a strong trend
remained (0.08< p<0.13). N54–6 per group for PCR. Statistical
analysis was completed using a one-way ANOVA with Tukey’s post
hoc test at each time point. Significantly different groups were
denoted with letters with “a” and “b” denoting statistical significance
between the two groups: day 7 (p <.001) and day 14 (p <.0001)
FIGURE 7 Myelinated axons 4 weeks after injury. (A) Immunofluorescence of myelinated (NF2001/MBP1/P0 red/green/blue, respectively)
and total (NF2001: red) axons from bridge implants (scale bar 200 mm). Dashed line indicates border between bridge implant and host
tissue. NF2001/MBP1 Immunofluorescence at higher magnification from bridges delivering (B) No virus (empty), (C) F-LUC, or (D) IL-10
(scale bar 50 mm). Brightness and contrast were adjusted for clarity. Arrows note unmyelinated axons (red), oligodendrocyte myelinated
axons (yellow), and Schwann cell myelinated axons (blue). (E) Quantification of total axon numbers, total myelinated axons, and Schwann
cell myelinated axons. (mean 1/2SEM)
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The studies reported herein employ lentiviral delivery from bridges in
order to induce sustained expression of the anti-inflammatory cytokine
IL-10 to modulate the inflammatory response. Previous reports of lenti-
viral delivery from a bridge implanted into the injured spinal cord have
demonstrated sustained expression for at least 8 weeks, with maximal
expression localized within the bridge and decreased expression both
rostral and caudal to the bridge.60,63 IL-10 has been reported in some
studies to be neuroprotective, reduce secondary inflammation, and
reduce lesion volume; however, others have suggested that IL-10 has
insignificant effects on spinal cord regeneration. This discrepancy in
responses may result from the different models of SCI, or from differ-
ences in delivery. Notably, IL-10 does not pass the blood-brain barrier
(BBB), and must be delivered either locally or pass through a disrupted
BBB following injury. IL-10 also is unstable with a short half-life of
1.1–2.6 hrs, necessitating repeated doses or sustained expression
approaches.74 Systemic overexpression of IL-10 has been investigated,
yet this approach is associated with peripheral neuropathy and demye-
lination of the sciatic nerve.71 Systemic delivery of IL-10 protein has
had conflicting results: either increasing tissue damage with impaired
locomotion or reducing lesion size.47,75 IL-10 poliovirus elevated IL-10
for 4 days with modestly improved function, and intrathecal injection
of HSV-encoding IL-10 improved axonal sparing and functional recov-
ery.37,38 Despite several studies investigating IL-10 delivery for SCI, the
effects of sustained localized delivery on dampening and resolving the
immune response to promote regeneration have not previously been
studied.59 and are the focus of the studies herein.
We initially demonstrate that delivery of IL-10-encoding lentivirus
can decrease PMN infiltration into biomaterial bridges implanted fol-
lowing SCI, and that though the loading of lentivirus to bridges may
promote PMN infiltration, IL-10 over-expression reverses this effect.
Although PMNs are transient participants in the immune response fol-
lowing injury to peripheral tissues, they can persist for weeks after
injury to the spinal cord.12,20 Furthermore, though virus delivery from
biomaterials can be used to enhance nerve regeneration,54,76 addition
of virus to the biomaterial platform can increase the extent of cell
infiltration.77–79 Secretion of chemokines from the increased immune
cells may be responsible for the increase in PMN infiltration at day 7
and 28 reported here (Figure 3C), though increased cytokines would
also be expected to simultaneously influence macrophage infiltration,
which was not observed and is in agreement with a previous report.58
Due to their primarily bactericidal role in wound healing, PMNs are not
expected to provide neuroprotection and are primarily detrimental in
SCI.12 PMNs (and macrophages) release cytokines, free radicals, eicosa-
noids, and proteases, which are toxic to neurons and glia. In particular,
superoxide, nitric oxide, and peroxynitrite are highly toxic and create
irreversible damage to cellular components, inducing apoptosis.80 How-
ever, tail vein administration of the RB6-8C5 Ly6G/Gr-1 antibody,
which selectively depleted the hematogenous PMN population by
more than 90%, resulted in less glial scarring, decreased spared tissue,
and worse BMS functional results.81 Cytokines released by neutrophils
may be necessary for sufficient formation of reactive astrocytes to seal
the injury and re-establish the BBB. In contrast, reducing infiltration of
PMNs (#70%) and macrophages (#36%) by administration of antibodies
against CD11d/CD18 results in less ROS, decreased Caspase 3, and
improved functional recovery.82–84 These results suggest that though
PMNs are essential for the initiation of proper wound healing in the
acute injury stage, strategies that mitigate PMN presence in later
stages of injury may improve regeneration. Notably, the decrease
reported herein regarding the chronic persistence of PMNs, a feature
characteristic of mouse and human SCI, has not been previously
reported12,20,25 These reports have demonstrated PMNs lasting
through 180 days in mice and 12 months in humans.20,85 Neutrophils
are generally believed to aggravate SCI, though there may be some
beneficial function that remains unidentified.20 Taken together, the
sustained production of IL-10 through lentivirus transduction alone, or
preferably as part of a combinatorial therapy, may prove crucial to
reducing the secondary damage and cell death associated with PMN
infiltration11 and enhancing regeneration.
Macrophage phenotype, and to some extent number, was influ-
enced by lentiviral delivery of IL-10. Flow cytometry and immunofluo-
rescence staining demonstrated no changes in F4/801 macrophage
numbers at day 7 and 28 between conditions. At day 14, quantification
revealed a 1.7-fold increase in the number of F4/801 macrophages
with expression of IL-10 relative to the control conditions (p< .05).
These results were expected, as macrophage number is known to peak
around Day 7-10 and plateau for several days before decreasing
throughout the intermediate and chronic phase.12,20 More importantly,
IL-10 production altered macrophage polarity with a substantial (3-
fold) increase in M2 (F4/801/arginase1) macrophage numbers at Day
14 relative to empty bridges (p< .05). While the number of arginase1
macrophages was not elevated at Day 7 or Day 28, arginase mRNA
was upregulated at Day 7 and 14, and trended upward at Day 28. Mac-
rophages can have varying degrees of arginase expression as seen in
FIGURE 8 Functional recovery induced by IL-10 overexpression.
The BMS was used to test for differences in motor function in the
hindlimb ipsilateral to SCI (n515 per group). Statistical analysis
was completed using a two-way ANOVA with repeated measures
and a Sidak correction for multiple comparisons. Significant differ-
ences notated with *** (p< .001) or **** (p< .0001)
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Figure 4, which may depend on the specific subtype and phase of
regeneration (inflammatory, proliferative, or remodeling).44 IL-10
known for its ability to upregulate expression of IL-4Ra, which may
synergize with IL-4 dependent arginase expression.86 Additionally,
alternatively activated (M2) macrophages produce IL-10, potentially
creating a feed forward process when IL-10 is overexpressed.
IL-10 expression influenced the relative distribution of three
macrophage morphologies: elongated, fibrous cells, round cells with
a prominent F4/80 border, and FBGCs. The significance of these
morphologies is unclear, and the literature has little information
about the relationship between macrophage morphology and phe-
notype. In vitro studies, in particular, have been conflicting. Human
macrophages polarized to M1/M2 with LPS/IFNg and IL-4 respec-
tively that were cultured on tissue culture plastic or within collagen
gels exhibited elongated morphologies for M1 macrophages and
round, less adherent morphologies for M2 macrophages.87 In con-
trast, when C57BL/6 macrophages are cultured on fibronectin-
coated polydimethylsiloxane molds, M1 macrophages have a
rounded morphology while M2 macrophages have a fibroblast-like
morphology.88 Moreover, McWhorter et al. demonstrated that sub-
strates patterned with lines (width 20 mm) could elongate macro-
phages leading to upregulated arginase expression.
In vivo characterization of the relationship between macrophage
phenotype and morphology has similarly been conflicting. One hypoth-
esis is that the elongated F4/801 cells are activated hematogenous
macrophages, while the round cells are activated resident microglia.
Microglia are well known to proceed from a highly ramified morphol-
ogy toward an amoeboid morphology as they become activated and
phagocytic after injury.89 Unfortunately, antibodies have not been
identified to accurately distinguish macrophages from microglia using
immunohistochemistry, though future studies using genetic models
such as cr2rfp::Cx3cr1gfp mice90 have the potential to distinguish cell
morphology, phenotype, and lineage. Alternatively, these different mor-
phologies may represent distinct M2 phenotypes. Shechter et al. selec-
tively ablated monocyte-derived macrophages followed by adoptive
transfer of monocytes.41 The exogenous monocytes differentiated into
macrophages with an activated morphology, which was manifested by
a large cell body with few to no processes, arginase expression, and IL-
10 release. These factors suggested an anti-inflammatory phenotype,
and the monocytes contributed to regeneration.41 A subset of infiltrat-
ing monocyte-derived, anti-inflammatory macrophages may be essen-
tial for recovery, though these cells represent a specific subset of M2
macrophages and will require further characterization.91,92
The round macrophages with prominent F4/801 borders may
be undergoing fusogenesis. FBGCs have not been extensively stud-
ied in the spinal cord and their impact on spinal cord regeneration is
unknown. Fusion has been proposed to begin with the creation of
fusion-competent macrophages by IL-4/IL-13 and/or DAP12/
TREM-2 interactions between adjacent macrophages,93 followed by
CCL2-mediated chemotaxis and E-cadherin-based macrophage
adhesion. Despite this simple model, the general requirements for
fusion are not fully understood in that it is not clear what role phag-
ocytic capability, macrophage subtype, and material interactions
play in their formation.93 Additionally, though IL-4 and IL-13 are typ-
ically thought of as cytokines associated with macrophage fusion,93
IL-10 co-localizes with M2 macrophages at sites of macrophage
fusion during FBGC development.94 Whether IL-10 induces or facili-
tates fusion or if FBGCs are formed by IL-10-producing macro-
phages remains unclear.
Although IL-10 did not increase axon numbers in the bridge, IL-10
robustly improved motor function after SCI (Figure 8). IL-10 may act to
moderate the deleterious immune response, resulting in improved axon
sparing. Increased sparing with increased IL-10 expression is consistent
with previous reports, which have demonstrated that IL-10 reduces
loss of neurons and oligodendrocytes directly through trophic sup-
port38 and indirectly by limiting the immune response.59 Additionally,
in our past work, differences in numbers of regenerating axons
between conditions become more pronounced at later time points.54
Thus, improved motor function observed in the current study suggests
improved sparing and plasticity instead of regeneration. While these
data suggest that IL-10 overexpression from PLG bridges effectively
improves function after SCI, delivery of IL-10 in combination with neu-
rotrophic factors known to promote axon regeneration, such as
neurotrophin-3 (NT-3),54,57 may act synergistically to further improve
both sparing and regeneration.
The present study indicates that immobilization of IL-10 lentivirus
onto multiple channel bridges alters the immune response to create a
microenvironment that is permissive to regeneration and shows prom-
ise as a translatable strategy. The bridges used are made of PLG, a bio-
material that has been utilized for decades in FDA-approved
applications, including biodegradable sutures and drug delivery
vehicles.95 PLG is easily sterilized for clinical using standard techniques,
most commonly g-irradiation.96 Though safety has been cited as a con-
cern for lentiviral vectors, there are ongoing clinical trials using lentivi-
rus without adverse effects or evidence of insertional
mutagenesis.97–99 Pyrogens from virus production can be limited by
purification through gravity-flow columns to yield endotoxin-free, con-
centrated plasmid, as done in these studies. Furthermore, good manu-
facturing practices (GMP) have been developed for large-scale
preparation of lentivirus for clinical use.98,100
Finally, the hemisection model of SCI, while not perfectly repre-
sentative of all SCI, is a translatable platform for studying the injury site
and developing treatments. While contusive injuries represent the
majority of SCI in the developed world, at least 28% of cases in the US
military are penetrating,101 and in South Africa, more than 60% of SCI
is categorized as penetrating.102 Moreover, the initial deficits resulting
from penetrating SCI exhibit substantially less improvement over time
than those from contusive injuries.103 For more severe contusions,
even if tissue architecture is initially preserved, secondary damage
results in cavitation, loss of parenchyma, and glial scarring. Severe con-
tusions and penetrating injuries may require a biomaterial bridge to
provides a permissive pathway for regenerating neurons to cross the
injury site and reconnect spinal pathways through true axonal regener-
ation, as opposed to local sprouting.104
MARGUL ET AL. | 145
5 | CONCLUSIONS
We report that delivery of IL-10-encoding lentivirus from multiple-
channel bridges to reduce the innate immune response following injury.
IL-10 overexpression reduces PMN infiltration into the injured spinal
cord compared to the delivery of control lentivirus. IL-10 overexpres-
sion induced arginase expression in macrophages and substantially
altered macrophage morphology. Additionally, IL-10 lentivirus resulted
in substantially improved motor function. This result indicates that IL-
10 will be an essential component of subsequent combinatorial gene
therapies in order to reduce cell death and inhibition.
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